Medicis (plaintiff) filed a complaint
against Alkem, The Pharma Network and Ascend
(defendants) in the U.S. District Court of Delaware (case no. 1:12-cv-01663)
on Wednesday, December 05, 2012, for filing ANDA for generic version of Solodyn®.
Medicis Pharmaceutical Corporation is a specialty
pharmaceutical company in the United States focusing primarily on the treatment
of dermatological and aesthetic conditions. Their products include Solodyn and
Ziana for treating acne. Alkem is in the business of manufacturing generic
pharmaceutical drugs. The Pharma Network (TPN) is a wholly owned subsidiary of
Alkem. Ascend markets pharmaceutical products including generic drugs
manufactured by Alkem.
The patents involved in this suit are
|
Patent Number
Current Assignee[i]
|
Issued Date
|
Expiration
Date[ii]
|
Title
|
|
|
Jun 01, 1999
|
Feb 19, 2018
|
Method for the treatment of acne
|
|
|
Sep 07, 2010
|
Jun 24, 2025
|
Minocycline
oral dosage forms for the treatment of acne
|
|
|
Sep 18, 2012
|
Jun 24, 2025
|
Minocycline oral dosage forms for the treatment of acne
|
Note: Table information sourced from Maxval’s Assignment Database and Litigation Database.
Medicis is the current holder[iii] of the New
Drug Application (NDA) no. 050808 for Solodyn® (source: Maxval’s Patent Marker) that is
approved by FDA. Solodyn® is
a tetracycline antibiotic approved to treat pimples and red bumps occurring
with moderate to severe acne in people above 12 years. The complaint is filed
against the defendants for seeking FDA approval with the Abbreviated New Drug Application (ANDA) no. 204453 (the Alkem ANDA)
to market a generic version of Solodyn® that
infringes the above patents.
Plaintiff has recently filed suit against the companies below:
|
Company |
Case Number
|
Date Filed
|
Status |
|
Sidmak |
12/05/2012
|
Pending |
|
|
Actavis |
08/31/2012
|
Pending |
|
|
Zydus |
06/05/2012
|
Pending |
If you are
interested in knowing more about the cases filed by Medicis, please contact us.
For more
details, visit MaxVal-IP and
subscribe to our Litigation
Alerts.
[i]MaxVal offers Patent
Assignment Alert service where subscribers receive email alerts when
assignments relating to target applications, patents or entities of interest
are recorded.
[ii]Expected
expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent terms and
expiration dates for U.S. utility patents.
[iii]Patent Marker provides an online environment for patentees to
virtually mark products and search for patent related information.
No comments:
Post a Comment